These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30131374)

  • 21. Creating a market for IQOS: analysis of Philip Morris' strategy to introduce heated tobacco products to the Australian consumer market.
    Watts C; Burton S; Freeman B
    Tob Control; 2022 May; 31(3):458-463. PubMed ID: 33191270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Categorizing IQOS-Related Twitter Discussions.
    Barker JO; Vassey J; Chen-Sankey JC; Allem JP; Cruz TB; Unger JB
    Int J Environ Res Public Health; 2021 Apr; 18(9):. PubMed ID: 33946546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
    Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
    Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marketing IQOS in a dark market.
    Mathers A; Schwartz R; O'Connor S; Fung M; Diemert L
    Tob Control; 2019 Mar; 28(2):237-238. PubMed ID: 29724866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of FDA's IQOS marketing authorisation and its policy impacts.
    Lempert LK; Glantz S
    Tob Control; 2020 Jun; ():. PubMed ID: 32601147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modelling the impact of a new tobacco product: review of Philip Morris International's Population Health Impact Model as applied to the IQOS heated tobacco product.
    Max WB; Sung HY; Lightwood J; Wang Y; Yao T
    Tob Control; 2018 Nov; 27(Suppl 1):s82-s86. PubMed ID: 30275170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in Biomarkers of Exposure on Switching From a Conventional Cigarette to Tobacco Heating Products: A Randomized, Controlled Study in Healthy Japanese Subjects.
    Gale N; McEwan M; Eldridge AC; Fearon IM; Sherwood N; Bowen E; McDermott S; Holmes E; Hedge A; Hossack S; Wakenshaw L; Glew J; Camacho OM; Errington G; McAughey J; Murphy J; Liu C; Proctor CJ
    Nicotine Tob Res; 2019 Aug; 21(9):1220-1227. PubMed ID: 29912406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towards a greater understanding of the illicit tobacco trade in Europe: a review of the PMI funded 'Project Star' report.
    Gilmore AB; Rowell A; Gallus S; Lugo A; Joossens L; Sims M
    Tob Control; 2014 May; 23(e1):e51-61. PubMed ID: 24335339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IQOS - a heat-not-burn (HnB) tobacco product - chemical composition and possible impact on oxidative stress and inflammatory response. A systematic review.
    Kopa PN; Pawliczak R
    Toxicol Mech Methods; 2020 Feb; 30(2):81-87. PubMed ID: 31532297
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of IQOS risk perceptions on cigarette smoking behaviours: results from a prospective pilot study.
    DeAtley T; Stone MD; Strasser AA; Audrain-McGovern J
    Tob Control; 2024 Feb; 33(2):263-266. PubMed ID: 36002165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heated tobacco product regulation under US law and the FCTC.
    Lempert LK; Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s118-s125. PubMed ID: 30291201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of reduced-risk nicotine-delivery products on smoking prevalence and cigarette sales: an observational study.
    Pesola F; Phillips-Waller A; Beard E; Shahab L; Sweanor D; Jarvis M; Hajek P
    Public Health Res (Southampt); 2023 Sep; 11(7):1-39. PubMed ID: 37795840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IQOS
    Adriaens K; Gucht DV; Baeyens F
    Int J Environ Res Public Health; 2018 Dec; 15(12):. PubMed ID: 30567400
    [No Abstract]   [Full Text] [Related]  

  • 34. IQOS marketing strategies at point-of-sales: a cross-sectional survey with retailers.
    Bar-Zeev Y; Berg CJ; Khayat A; Romm KF; Wysota CN; Abroms LC; Elbaz D; Levine H
    Tob Control; 2023 Aug; 32(e2):e198-e204. PubMed ID: 35140170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heated tobacco products for smoking cessation and reducing smoking prevalence.
    Tattan-Birch H; Hartmann-Boyce J; Kock L; Simonavicius E; Brose L; Jackson S; Shahab L; Brown J
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013790. PubMed ID: 34988969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Informing iQOS Regulations in the United States: A Synthesis of What We Know.
    Berg CJ; Bar-Zeev Y; Levine H
    Sage Open; 2020; 10(1):. PubMed ID: 32719733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IQOS point-of-sale marketing strategies in Israel: a pilot study.
    Bar-Zeev Y; Levine H; Rubinstein G; Khateb I; Berg CJ
    Isr J Health Policy Res; 2019 Jan; 8(1):11. PubMed ID: 30642383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Awareness and interest in IQOS heated tobacco products among youth in Canada, England and the USA.
    Czoli CD; White CM; Reid JL; OConnor RJ; Hammond D
    Tob Control; 2020 Jan; 29(1):89-95. PubMed ID: 30696783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of IQOS health warnings and modified risk claims among young adult cigarette smokers and non-smokers.
    Mays D; Johnson AC; Glasser A; Mercincavage M; Strasser AA
    Tob Control; 2023 Jul; 32(4):505-508. PubMed ID: 34716283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of FDA endorsement and modified risk versus exposure messaging in IQOS ads: a randomised factorial experiment among US and Israeli adults.
    Berg CJ; Duan Z; Wang Y; Thrasher JF; Bar-Zeev Y; Abroms LC; Romm KF; Khayat A; Levine H
    Tob Control; 2024 Mar; 33(e1):e69-e77. PubMed ID: 36428095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.